Company
InvivoGen was established in 1977, the first biotechnology company in France. We are serving life scientists worldwide with innovative and high-quality research reagents. Specializing in innate immunity, InvivoGen scientists foster the design and development of new tools and services to keep the pace with scientific breakthroughs. The leading active pipelines of InvivoGen facilitate cutting-edge and translational research.\u2028\u2028
InvivoGen Limited was incorporated in the Hong Kong Science and Technology Park (HKSTP) in 2014. We aim at developing business opportunities and providing professional support to life science researchers in Asian-Pacific region.
Technology
Innovation within Reach
InvivoGen has been involved in handling microbes to produce a wide range of biological molecules for over forty years. In 1970s, Dr. Gérard Tiraby, the founder of InvivoGen and the professor of microbiology at the Université Toulouse III, discovered a unique antibiotic and named it Zeocin®; an anti-mycoplasma antibiotic, Plasmocin®, was also developed in the early 1980s and has been widely used by researchers to prevent or remove mycoplasma contamination in cell culture. In 1997, there was a ground breakthrough in the research of innate immune sensors. Thanks to our unique knowledge in microbiology, InvivoGen was the first to commercialize Toll-Like Receptors (TLRs) ligands in 2000 and has become the supplier with the most comprehensive range of products for innate immunology research.
As innate immunity expands to interdisciplinary field of study. InvivoGen therefore keeps enlarging our library of products and services for different research fields such as cancer immunotherapy, gene therapy, cell therapy, vaccine development and bioactivity screening for artificial intelligence drug discovery, etc.
InvivoGen’s Life Science Research Products
Tools for detection and elimination of microbial contaminants
Selective antibiotics
Pattern recognition receptors (PRR) agonists and antagonist
Genes and proteins related to immunology
Reporter cell lines
Immune checkpoint antibodies
Vaccine adjuvants
COVID-19-related products
InvivoGen has been involved in handling microbes to produce a wide range of biological molecules for over forty years. In 1970s, Dr. Gérard Tiraby, the founder of InvivoGen and the professor of microbiology at the Université Toulouse III, discovered a unique antibiotic and named it Zeocin®; an anti-mycoplasma antibiotic, Plasmocin®, was also developed in the early 1980s and has been widely used by researchers to prevent or remove mycoplasma contamination in cell culture. In 1997, there was a ground breakthrough in the research of innate immune sensors. Thanks to our unique knowledge in microbiology, InvivoGen was the first to commercialize Toll-Like Receptors (TLRs) ligands in 2000 and has become the supplier with the most comprehensive range of products for innate immunology research.
As innate immunity expands to interdisciplinary field of study. InvivoGen therefore keeps enlarging our library of products and services for different research fields such as cancer immunotherapy, gene therapy, cell therapy, vaccine development and bioactivity screening for artificial intelligence drug discovery, etc.
InvivoGen’s Life Science Research Products
Tools for detection and elimination of microbial contaminants
Selective antibiotics
Pattern recognition receptors (PRR) agonists and antagonist
Genes and proteins related to immunology
Reporter cell lines
Immune checkpoint antibodies
Vaccine adjuvants
COVID-19-related products
